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Abstract 
In the ENSURE-AF study (NCT 02072434), edoxaban was compared to enoxaparin–warfarin in 2199 
patients undergoing electrical cardioversion of non-valvular atrial fibrillation (AF). In this multicenter 
PROBE trial, we analyzed patients randomized to enoxaparin–warfarin. We determined time to achieve 
therapeutic range (TtTR), time in therapeutic range (TiTR), their clinical determinants, relation to SAMe-
TT2R2 score, and impact on primary endpoints (composite of stroke, systemic embolic event [SEE], 
myocardial infarction [MI], and cardiovascular death [CVD] and composite of major + clinically relevant 
non-major [CRNM] bleeding). Among 1104 patients randomized to enoxaparin––warfarin, 27% were 
oral anticoagulant naïve. Mean age was 64.2±11 years and mean CHA2DS2-VASc score was 2.6. Mean 
TtTR was 7.7 days (median 7 days) and mean TiTR after reaching INR 2.0–3.0 was 71%. In 695 patients 
with INR <2.0 prior to first dose and who reached ≥2.0, 436 had a SAMe-TT2R2 score ≤2 and 259 a score 
of >2. On multivariate regression, an independent predictor of extended TtTR was creatinine clearance 
(CrCl) [P=0.02]. TtTR was marginally related to stroke/SEE/MI/CVD (P=0.06; OR=0.23, 95% CI 0.02–1.17) 
but not to any bleeding. Independent predictors of TiTR were prior VKA experience (P<0.01) and low 
HAS-BLED score (P=0.02). TiTR was related to any bleeding (P=0.02; OR=0.39, 95% CI 0.16–0.88), but not 
stroke/SE/MI/CVD. In this cohort of warfarin users with a high TiTR no difference was seen between 
TtTR and TiTR in relation to SAMe-TT2R2 score. In conclusion, even in this short-term study, TiTR was 
significantly related to bleeding events. 
Key Words: warfarin, time in therapeutic range, bleeding, stroke
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Introduction  
Effective stroke prevention in patients with atrial fibrillation (AF) requires the use of oral 
anticoagulation. In the historical randomized trials, the use of warfarin significantly reduced the risk of 
stroke (by 64%) and all-cause mortality (by 26%) when compared with placebo or control.1 However, the 
effectiveness and safety of warfarin is dependent upon the quality of anticoagulation control (time in 
therapeutic range [TiTR])2 even in the presence of a single stroke risk factor.3 Optimization of TiTR is 
dependent on many factors and the most common are included in the SAMe-TT2R2 score.
4 This score has 
been validated to aid clinical decision-making and has been shown to be predictive of labile INRs, 
bleeding, thromboembolism, and death, consequences of poor anticoagulation control.5-8 In the 
ENSURE-AF study, the oral factor Xa inhibitor edoxaban was compared to warfarin in 2199 patients 
undergoing electrical cardioversion of non-valvular AF.9 Ideal patient management requires optimization 
of warfarin therapy within a therapeutic range of international normalized ratio (INR) 2.0–3.0, especially 
in the peri-cardioversion period. Given the prospectively collected data in ENSURE-AF, we determined 
aspects of anticoagulation control in the warfarin arm of this randomized trial, in an ancillary analysis. 
 
Methods 
The design and principal results of the ENSURE-AF trial (NCT 02072434) have been published.9, 10 In 
brief, this was a multicenter, prospective, randomized, open-label, blinded-endpoint evaluation, parallel 
group Phase 3b clinical trial, in which patients with non-valvular AF undergoing electrical cardioversion 
were randomized to edoxaban or warfarin. Patients with an INR <2.0 at randomization received 
enoxaparin and daily warfarin until the INR was ≥2.0 and those with INR ≥2.0 at the time of 
randomization did not require enoxaparin and were treated with warfarin alone. Patients were stratified 
by anticoagulation strategy (transoesophageal echocardiography [TEE] or non-TEE strata, or whether 
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previously anticoagulation naïve or experienced, selected edoxaban dose, and region, as defined at 
randomization). For the present study, we confined our investigation to an analysis of the 1104 patients 
in the ENSURE-AF trial who were randomized to enoxaparin–warfarin.  
We determined the TtTR, TiTR, their clinical determinants and impact on efficacy and safety 
outcomes. For patients who had baseline INR <2.0 and reached INR ≥2.0 during the on-treatment 
period, TtTR was defined as the first date of INR ≥2.0 minus the date of first study drug administration. 
For patients who had 2.0 ≥ INR ≤ 3.0 during the on-treatment period, TiTR was defined as the percent of 
time in therapeutic range (2.0 ≥ INR ≤ 3.0) from the first date of 2.0 ≥ INR ≤3.0. 
Stroke and bleeding risk was defined by the CHA2DS2-VASc
11 and HAS-BLED12 scores, respectively, 
while the SAMe-TT2R2 score
5 was defined as summarized in the Data Supplement. 
The primary efficacy analysis was comparing the occurrence of a composite endpoint of stroke, 
systemic embolic event (SEE), myocardial infarction (MI), and cardiovascular death (CVD) between the 
edoxaban group and the enoxaparin–warfarin group from randomization to end of follow-up and was 
performed on the intention-to-treat population (all individuals who were enrolled into the study and 
randomly assigned). The primary safety endpoint of the trial was the composite of major + clinically 
relevant non-major (CRNM) bleeding which occurred during the on treatment period, defined as the 
time period the patient was taking study medication plus up to 3 days after the last dose for that time 
period. Any bleeding was defined as the composite of major + CRNM + minor bleeding from time of first 
administration of study drug to end of treatment +3 days. Patients were followed for 28 days on study 
drug after cardioversion + another 30 days to assess safety on an investigator-prescribed standard of 
care.  
The protocol and its amendments were approved by ethics committees or institutional review 
boards. All patients provided written informed consent prior to participation in the study. 
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 Time to therapeutic range was calculated for a subset of patients who were randomized to 
enoxaparin–warfarin, had INR <2.0 prior to first dose, and reached therapeutic range of ≥2.0 during the 
on treatment period. Time in therapeutic range (TiTR) was calculated for patients receiving enoxaparin–
warfarin who had INR between 2.0 and 3.0 during the on treatment period only. Mean TtTR and TiTR 
outcomes were provided for patients with SAMe-TT2R2 score ≤2 and >2, respectively. We also calculated 
time in therapeutic range by imputing between-visit INR using a linear interpolation method described 
by Rosendaal and colleagues.13 
For enoxaparin–warfarin patients, the clinical characteristics were summarized and the difference 
between OAC naïve and experienced were assessed using 2 sample t-test or Chi-square test. The clinical 
determinants of TtTR and TiTR were analyzed by a linear model including covariates of age, gender, 
region, race, creatinine clearance (CrCl), cardioversion approach, ethnicity, oral anticoagulant (OAC) 
experience, CHA2DS2-VASc score, HAS-BLED score, smoking/tobacco use, and alcohol use. The TtTR and 
TiTR data were dichotomized to show the relation of TtTR and TiTR to efficacy and safety outcomes. 
Odds ratios (ORs) and 95% confidence intervals (CIs) are presented.  
Efficacy and safety outcomes were compared between the patients who received enoxaparin–
warfarin and patients who received edoxaban from sites with mean TiTR ≤70% and >70%, respectively.  
 
Results 
Among 1104 patients randomized to enoxaparin–warfarin, 27% were naïve to OAC at randomization 
(Table 1). Mean age was 64.2 (standard deviation [SD] ±10.7) years and mean CHA2DS2-VASc score was 
2.6 (SD ±1.4). Overall mean time in therapeutic range as calculated using the Rosendaal method was 
60% (SD ±30.6) being higher in OAC-experienced patients versus OAC-naïve patients (P=0.001). 
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Mean TtTR was 7.7 days (median 7 days), with no difference between the OAC-experienced and 
OAC-naïve groups. Mean TiTR after reaching INR 2.0–3.0 on warfarin was 71%, which was significantly 
higher among patients who were OAC experienced (P=0.0204). 
The SAMe-TT2R2 score was not significantly different between the OAC experienced and naïve 
patients (P=0.777) but the proportion of patients with SAMe-TT2R2 score >2 was higher in the OAC-
experienced group (P=0.0176). In 695 patients with INR <2.0 prior to first dose and who reached 
therapeutic range of ≥2.0, 436 (63%) had a SAMe-TT2R2 score ≤2 and 259 (37%) had a SAMEe-TT2R2 
score of >2. Mean TtTR in these SAMe-TT2R2 score subgroups were similar. In the 974 patients with INR 
in range of 2.0–3.0 post first dose, TiTR was 71% vs 70% for patients with SAMe-TT2R2 score ≤2 and >2, 
respectively.  
 On multivariate regression, an independent predictor of extended TtTR was CrCl (P=0.017). 
Independent predictors of TiTR were prior vitamin K antagonist (VKA) experience (P=0.005) and low 
HAS-BLED score (P=0.019) [Table 2].  
On contingency table analysis, TtTR was marginally related to stroke/SEE/MI/CVD (P=0.06; OR [odds 
ratio]=0.23, 95% CI 0.02–1.17) but not to any bleeding (P=0.53; OR=0.72, 95% CI 0.28–1.80). TiTR was 
related to any bleeding (P=0.02; OR=0.39, 95% CI 0.16–0.88), but not stroke/SE/MI/CVD (P=0.31; 
OR=0.42, 95% CI 0.07–1.98) [Table 3]. Figure 1 illustrates these efficacy and safety outcomes in relation 
to TiTR.  
 
Discussion 
In this pre-specified analysis of a well-managed cohort of warfarin users in a clinical trial setting we 
found that the only independent determinant of TtTR was CrCl, while independent predictors of TiTR 
were prior VKA experience and low HAS-BLED score. Additionally, in this cohort with a high TiTR (>70%), 
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no difference was observed between mean TtTR and TiTR in regards to the SAMe-TT2R2 score. 
Nevertheless, even in this short-term study, TiTR was related to bleeding events. 
We found that an independent predictor of TtTR was CrCl, consistent with prior data showing the 
difficulties of managing warfarin in non-valvular AF patients with renal impairment.14 Improved TiTR in 
patients with prior VKA experience would be consistent with patients ‘experienced’ in handling and 
managing VKA, achieving better anticoagulation control—perhaps reflecting the impact of improved 
patient education and knowledge of potential food effects and drug interactions in this unblinded ‘open’ 
clinical trial design15,16 while low HAS-BLED scores may reflect less comorbidities and polypharmacy, 
leading to improved TiTR.  
These observations are relevant to the use of warfarin in a conventional (non-TEE) anticoagulation 
strategy for cardioversion, where there may be marked variability within and between patients in TtTR. 
This is of relevance given that delays in achieving therapeutic anticoagulation with a conventional 
warfarin strategy may prolong the time in AF, and could potentially extend the time to cardioversion 
and reduce the chance of successful cardioversion and maintenance of sinus rhythm. 
 
The TiTR when warfarin is used can be influenced by many clinical factors. The most common of 
which have been incorporated into the SAMe-TT2R2 score. Various studies have shown how the SAMe-
TT2R2 score can dichotomize those likely to do well on warfarin with a good TiTR (SAMe-TT2R2 score 0-2) 
versus those less likely to achieve good TiTR (SAMe-TT2R2 score >2).
6,17 Furthermore, the validated 
SAMe-TT2R2 score is predictive of labile INRs, as well as the adverse outcomes associated with poor 
anticoagulation control, such as thromboembolism, death and bleeding.8 Nonetheless, in this cohort 
with a high TiTR (>70%), the SAMe-TT2R2 score did not discriminate between mean TtTR and TiTR. 
Similar findings were noted in another observational cohort with high TiTR,18 although the short follow-
up and meticulous attention to achieving good TiTR may have reduced the predictive value of SAMe-
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TT2R2 in this clinical trial. Given that the SAMe-TT2R2 score was designed to help discriminate those likely 
or not to achieve good (or poor) TiTR, the score seems to perform best in settings with a broad range of 
TiTR control.19 Recent data published by Pokorney et al20 further suggest that prediction of stability for 
INR values among patients who receive long-term warfarin therapy is limited. 
Time to therapeutic range was not significantly related to stroke/SEE/MI/CVD or any bleeding, and 
this may reflect the ENSURE-AF trial design, where enoxaparin bridging was used in patients wherever 
INRs were suboptimal to allow optimized warfarin management to be compared with edoxaban.9 Also, 
the short follow-up in this relatively low risk population of patients with non-valvular AF selected for 
cardioversion may have influenced event rates. However, even in this cohort with high TiTR, there was a 
significant relation of TiTR to any bleeding, but not stroke/SEE/MI/CVD. The non-significant impact on 
the latter may reflect the low overall event rates in the trial, and the short follow-up period. 
Nonetheless, TiTR is also a strong determinant of bleeding risks on VKA, and our data support this 
relationship.2 
Although the ENSURE-AF trial is the largest study in AF peri-cardioversion to date, this study is 
limited by being a subgroup analysis of a selected clinical trial cohort, and the results may not be 
applicable to the general AF population. In the ‘real world’, adherence and quality of life on enoxaparin 
injections would be relevant considerations, but we mandated good adherence in this trial setting. Also, 
the low overall event rates and short follow-up period may have influenced outcome rates which may 
be underpowered. In the trial setting, much focus was made towards achieving good TTR (which was 
achieved, with TiTR >70%) and would not be reflective of ‘real world’ warfarin management in some 
healthcare settings. 
The high rate of patients not achieving therapeutic range reflects the short nature of follow-up (28 
days post-cardioversion plus 30 additional days), but we ensured adequate anticoagulation was 
administered by enoxaparin bridging to ensure no delays in cardioversion. 
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In this well-managed cohort of warfarin users with documented non-valvular AF in a clinical trial 
setting with a high TiTR (>70%), no difference was seen between TtTR and TiTR in relation to SAMe-
TT2R2 score. Even in this short term study, TiTR was significantly related to bleeding events. 
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Figure Legend 
Figure. Efficacy and safety outcomes in relation to TiTR. 
*Includes all patients from study sites where the mean TiTR of enoxaparin–warfarin patients was ≤70%.  
†Includes all patients from study sites where the mean TiTR of enoxaparin–warfarin patients was >70%. 
CRNM indicates clinically relevant non-major bleeding; CVD, cardiovascular death; MI, myocardial 
infarction; SEE, systemic embolic event; TiTR, time in therapeutic range.  
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Table 1. Clinical Characteristics of Patients Randomized to Enoxaparin–Warfarin 
Variable 
Whole 
Cohort 
(N=1104) 
Oral 
Anticoagulant 
Naïve 
(n=296) 
Oral 
Anticoagulant 
Experienced 
(n=808) 
P value 
Oral 
Anticoagulant 
Naïve vs 
Experienced 
Age 64.2 ± 10.7 64.3 (10.8) 64.1 (10.8) 0.7782 
Women 382 (35%) 110 (37%) 272 (34%) 0.2790 
CHA2DS2-VASc score 2.6 (1.4) 2.6 (1.4 ) 2.6 (1.4) 0.7666 
HAS-BLED score 0.9 (0.8) 0.8 (0.8) 0.9 (0.8) 0.0416 
Weight (kg) 91.2 (19.0) 91.8 (19.0) 90.9 (19.0) 0.5189 
Creatinine clearance 94.1 (34.7) 97.5 (34. 8) 92.9 (34.6) 0.0596 
Time in therapeutic  
   range (days)* 
59.8 (30.6) 54.4 (30.1) 61.8 (30.6) 0.0008 
SAMe-TT2R2 score 2.1 (1.3) 2.0 (1.2) 2.2 (1.3) 0.0777 
   0–2 63% 69% 61% 
0.0176 
   >2 37% 31% 39% 
Time to achieve 
therapeutic range (days) 
7.7 (5.1) 8.1 (4.5) 7.4 (5.4) 0.0662 
Time in therapeutic range 70.8 (27%) 67.4 (29%) 72.0 (27%) 0.0204 
*Calculated using the Rosendaal method.13 
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Values are mean (SD) unless otherwise specified. 
P-values are based on two sample t-test and Chi-square test for continuous variables and 
categorical variables, respectively.  
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Table 2. Clinical Determinants of Time to Achieve Therapeutic range and Time in Therapeutic 
Range 
Clinical Factor 
TtTR TiTR 
Coefficient 
Estimate 
(Standard 
Error) P value 
Coefficient Estimate 
(Standard Error) P value 
Age 0.01 (0.03) 0.871 0.11 (0.15) 0.458 
Women -0.17 (0.52) 0.741 1.03 (2.33) 0.658 
Non-white 0.97 (2.12) 0.647 0.29 (11.38) 0.980 
Eastern Europe -0.32 (0.52) 0.548 -1.23 (2.37) 0.604 
Middle East & Northern 
Africa 
0.24 (1.03) 0.817 -6.66 (4.98) 0.181 
North America 0.03 (0.99) 0.979 -8.77 (4.80) 0.068 
Western. Europe 0  0  
Creatinine Clearance 0.02 (0.01) 0.017 0.03 (0.04) 0.336 
Cardioversion approach     
Non-Transesophageal 
echocardiography 
0.19 (0.42) 0.653 -2.41 (1.91) 0.207 
Transesophageal 
echocardiography 
0  0  
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Hispanic  2.25 (1.95) 0.249 -9.79 (8.38) 0.243 
Non-Hispanic 0  0  
Anticoagulant experience     
   Experienced -0.72 (0.43) 0.097 6.07 (2.16) 0.005 
   Naive 0  0  
CHA2DS2-VASc score -0.26 (0.23) 0.254 0.40 (1.04) 0.702 
HAS-BLED score 0.15 (0.35) 0.668 -3.66 (1.56) 0.019 
Current smoker 0.24 (0.73) 0.745 4.26 (3.31) 0.199 
Former smoker -0.16 (0.53) 0.762 -0.47 (2.39) 0.843 
Never smoker 0  0  
Alcohol use (drinks/day)     
    None 4.13 (2.97) 0.165 -11.36 (10.58) 0.283 
    <1 4.66 (2.99) 0.119 -12.20 (10.62) 0.251 
     1–2 5.79 (3.06) 0.059 -13.11 (11.04) 0.235 
    >2 2.74 (3.43) 0.424 -20.37 (13.20) 0.123 
TiTR indicates time in therapeutic range; and TtTR, time to achieve therapeutic range. 
 
Multivariate analysis is based on a linear model including covariates of age, gender, region, race, 
creatinine clearance, cardioversion approach, ethnicity, anticoagulant experience, CHA2DS2-VASc 
score, HAS-BLED score, smoking/tobacco use, and alcohol use.  
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Table 3. Relation of Time to Achieve Therapeutic Range and Time in Therapeutic Range to 
Efficacy and Safety Outcomes 
 
TtTR ≤6 TtTR >6 
Odds Ratio 
(95% CI) P-value 
Stroke/systemic embolic 
event/myocardial 
infarction/cardiovascular 
death 
8/337 (2%) 2/358 (<1%) 0.23 (0.02–1.17) 0.06 
Any Bleeding 13/337 (4%) 10/358 (3%) 0.72 (0.28–1.80) 0.53 
     
 
TiTR ≤70% TiTR >70%* 
Odds Ratio 
(95% CI) 
P-value 
Stroke/systemic embolic 
event/myocardial 
infarction/cardiovascular 
death 
6/446 (1%) 3/528 (<1%) 0.42 (0.07–1.98) 0.31 
Any Bleeding 21/446 (5%) 10/528 (2%) 0.39 (0.16–0.88) 0.02 
TtTR indicates time to achieve therapeutic range; and TiTR, time in therapeutic range. 
*Patient-based analysis. 
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